Literature DB >> 19094618

[Liver resection in hepatolithiasis: 20-year's evolution].

Zhi-qiang Huang1, Xiao-qiang Huang, Wen-zhi Zhang, Li-ning Xu, Tao Yang, Ai-qun Zhang, Jia-hong Dong.   

Abstract

OBJECTIVE: To analyze operative and perioperative factors associated with hepatectomy in hepatolithiasis.
METHODS: 245 consecutive hepatolithiasis patients undergoing hepatectomy from January 1986 to December 2005 at Chinese People's Liberation Army General Hospital were investigated retrospectively according to medical documentation.
RESULTS: Hepatolithiasis accounted for 29.6% (245/827) in all benign liver diseases treated with hepatectomy during this time period. There were 88 cases in male and 157 cases in female, the average age was (46.9 +/- 11.3) years. Cases of right liver resection and hepatic segments resection were much more than that in 1963 - 1985. Blood transfusion during operation was given in 45.3% of cases. Complication incidence was 16.3%, with infection 3.3% and bile leakage 2.4%. Length of stay after operation was (15.7 +/- 9.2) days. Perioperative mortality rate was 0.4% (1/245).
CONCLUSIONS: Individualized hepatectomy is the important surgical treatment of hepatolithiasis. Hepatectomy can be performed safely with low mortality and low complication incidence, provided that it is carried out with optimized perioperative management and innovative surgical technique.

Entities:  

Mesh:

Year:  2008        PMID: 19094618

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  2 in total

1.  Liver Resection for Primary Intrahepatic Stones: Focus on Postoperative Infectious Complications.

Authors:  Gennaro Clemente; Agostino M De Rose; Rita Murri; Francesco Ardito; Gennaro Nuzzo; Felice Giuliante
Journal:  World J Surg       Date:  2016-02       Impact factor: 3.352

Review 2.  Double common bile duct with choledochal cyst and cholelithiasis: report of a case.

Authors:  Geng Chen; Huaizhi Wang; Leida Zhang; Zhihua Li; Ping Bie
Journal:  Surg Today       Date:  2013-04-04       Impact factor: 2.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.